- Home
- LFCR vs CAPR Comparison
LFCR vs CAPR Comparison
Compare LFCR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- CAPR
- Stock Information
- Founded
- LFCR 1986
- CAPR 2005
- Country
- LFCR United States
- CAPR United States
- Employees
- LFCR N/A
- CAPR N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFCR Health Care
- CAPR Health Care
- Exchange
- LFCR Nasdaq
- CAPR Nasdaq
- Market Cap
- LFCR 308.8M
- CAPR 324.6M
- IPO Year
- LFCR N/A
- CAPR N/A
- Fundamental
- Price
- LFCR $7.61
- CAPR $6.28
- Analyst Decision
- LFCR Buy
- CAPR Strong Buy
- Analyst Count
- LFCR 4
- CAPR 8
- Target Price
- LFCR $8.00
- CAPR $24.75
- AVG Volume (30 Days)
- LFCR 108.3K
- CAPR 1.4M
- Earning Date
- LFCR 08-07-2025
- CAPR 08-11-2025
- Dividend Yield
- LFCR N/A
- CAPR N/A
- EPS Growth
- LFCR N/A
- CAPR N/A
- EPS
- LFCR N/A
- CAPR N/A
- Revenue
- LFCR $128,867,000.00
- CAPR $13,392,150.00
- Revenue This Year
- LFCR $4.78
- CAPR N/A
- Revenue Next Year
- LFCR $12.02
- CAPR $6,061.53
- P/E Ratio
- LFCR N/A
- CAPR N/A
- Revenue Growth
- LFCR 0.47
- CAPR N/A
- 52 Week Low
- LFCR $3.68
- CAPR $3.98
- 52 Week High
- LFCR $8.85
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- LFCR 53.94
- CAPR 36.33
- Support Level
- LFCR $7.33
- CAPR $6.17
- Resistance Level
- LFCR $7.73
- CAPR $7.30
- Average True Range (ATR)
- LFCR 0.30
- CAPR 0.43
- MACD
- LFCR 0.03
- CAPR -0.11
- Stochastic Oscillator
- LFCR 65.33
- CAPR 4.53
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.